Application of ciprofibrate in preparation of medicine for resisting hepatitis B virus

By using ciprofibrate to reduce the expression of hepatitis B virus antigen and inhibit viral replication, the problem that existing drugs cannot protect healthy hepatocytes is solved, effective prevention and treatment of hepatitis B virus is achieved, and patient compliance is improved and security.

CN119033748AActive Publication Date: 2024-11-29NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411152115.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-21
Publication Date
2024-11-29
Estimated Expiration
2044-08-21

AI Technical Summary

Technical Problem

Existing anti-hepatitis B virus drugs cannot effectively protect healthy hepatocytes from reinfection, and interferon needs to be injected, which has great side effects. Third-generation nucleotide analogs require lifelong use and are difficult to completely remove the virus.

Method used

Using ciprofibrate as a drug to reduce the expression of hepatitis B surface antigen HBsAg, hepatitis B e antigen HBeAg and hepatitis B core antigen HBcAg, inhibit the infection and replication of hepatitis B virus, protect new hepatitis cells, and provide tablets, granules or liquid preparations. form.

Benefits of technology

Cyprofacter can effectively inhibit hepatitis B virus infection, reduce the expression of viral antigens, protect new liver cells, prevent and treat diseases caused by hepatitis B virus, such as liver failure, cirrhosis and hepatocellular carcinoma, with few side effects and no need Subcutaneous injection, the patient has high compliance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033748A_ABST
    Figure CN119033748A_ABST
Patent Text Reader

Abstract

The invention relates to an application of ciprofibrate in preparation of an anti-hepatitis B virus drug, and belongs to the technical field of biological medicines. The invention provides an application of ciprofibrate in preparation of a medicine for resisting hepatitis B virus. The ciprofibrate reduces the expression quantities of hepatitis B surface antigen HBsAg, hepatitis B e antigen HBeAg and hepatitis B core antigen HBcAg of human primary cells infected with the hepatitis B virus, inhibits hepatitis B virus infected cells, inhibits proliferation and replication of the hepatitis B virus, can protect new liver cells from being infected again, has the effect of resisting the hepatitis B virus, and can be used for preparing a medicine for treating the hepatitis B virus. Therefore, diseases caused by the hepatitis B virus are prevented and treated. The ciprofibrate as a lipid-regulating drug has small side effects, does not need subcutaneous injection, and has high patient compliance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of biomedicine, and in particular to the application of ciprofibrate in the preparation of ciprofibrate and in the preparation of drugs for resisting hepatitis B virus. Background Art

[0002] Hepatitis B virus (HBV) infection and its related diseases affect more than 250 million people worldwide. Nearly 820,000 people die each year from complications of liver failure, cirrhosis and hepatocellular carcinoma (HCC) caused by persistent HBV infection. HBV infection remains a major global public health problem. Existing therapeutic drugs include pegylated interferon α and third-generation nucleotide analogs. Pegylated interferon α exerts its antiviral effect by regulating immune responses or directly inhibiting viral replication in hepatocytes. Third-generation nucleotide analogs can inhibit HBV replication in host hepatocytes by targeting HBV polymerase to inhibit viral reverse transcription.

[0003] However, pegylated interferon α needs to be administered by injection, patient compliance is poor, and interferon has significant side effects. Although third-generation nucleotide analogs can reduce the activity of HBV polymerase, it is difficult to completely eliminate the virus, and most patients need to take them for life. Although pegylated interferon α and third-generation nucleotide analogs can inhibit the expression of HBV antigens, they cannot completely eliminate them and cannot protect new liver cells from infection.

[0004] Existing drugs for treating diseases caused by HBV mainly eliminate the virus by inhibiting HBV replication. These drugs only work on HBV in infected liver cells and cannot protect healthy liver cells from HBV reinfection. Summary of the invention

[0005] The purpose of the present invention is to overcome the shortcomings of the prior art and provide a new drug for inhibiting hepatitis B virus infection, and the application of ciprofibrate in the preparation of drugs against hepatitis B virus.

[0006] To achieve the above object, the technical solution adopted by the present invention is:

[0007] In a first aspect, the present invention provides the use of ciprofibrate in the preparation of an anti-hepatitis B virus drug.

[0008] Furthermore, the drug is a drug for inhibiting hepatitis B virus infection.

[0009] Furthermore, the drug is a drug that inhibits the replication and / or proliferation of hepatitis B virus.

[0010] In a specific embodiment of the present invention, the drug is a drug that reduces the expression level of at least one of hepatitis B surface antigen HBsAg, hepatitis B e antigen HBeAg and hepatitis B core antigen HBcAg.

[0011] Furthermore, the medicine also contains pharmaceutically acceptable additives and / or excipients and / or carriers.

[0012] Furthermore, the medicine is in the form of tablets, granules or liquid preparations.

[0013] In a second aspect, the present invention provides the use of ciprofibrate in the preparation of a medicament for preventing and / or treating diseases caused by hepatitis B virus.

[0014] Furthermore, the medicine is a medicine for preventing and / or treating hepatitis B.

[0015] Furthermore, the drug is a drug for preventing and / or treating liver failure, cirrhosis and hepatocellular carcinoma and their complications caused by hepatitis B virus.

[0016] Furthermore, the drug is an anti-hepatitis B virus drug.

[0017] Furthermore, the drug is a drug for inhibiting hepatitis B virus infection.

[0018] Furthermore, the drug is a drug that inhibits the replication and / or proliferation of hepatitis B virus.

[0019] In a specific embodiment of the present invention, the drug is a drug that reduces the expression level of at least one of hepatitis B surface antigen HBsAg, hepatitis B e antigen HBeAg and hepatitis B core antigen HBcAg.

[0020] Compared with the prior art, the beneficial effects of the present invention are as follows: the existing anti-HBV drugs mainly eliminate the HBV by inhibiting viral replication. These drugs only work on the HBV in the infected liver cells, but cannot protect the healthy liver cells from being infected by the HBV again. The present invention has found that ciprofibrate reduces the expression of HBsAg, HBeAg and HBcAg in human primary cells infected with the HBV, inhibits the infection of the HBV cells, inhibits the proliferation and replication of the HBV, can protect the new liver cells from being infected again, has an anti-HBV effect, and thus prevents and treats diseases caused by the HBV. Ciprofibrate Ciprofibrate is a peroxisome proliferator-activated receptor agonist. As a lipid-regulating drug, it has few side effects, does not require subcutaneous injection, and has high patient compliance. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1This is the binding status of different small molecule compound probes with hepatitis B surface antigen L-HBsAg protein.

[0022] Figure 2 The effect of ciprofibrate on the content of HBsAg and HBeAg after human primary cells were infected with HBV virus. Among them, A is HBsAg; B is HBeAg.

[0023] Figure 3 This is an immunofluorescence staining image of human primary cells after ciprofibrate infected human primary cells with HBV virus.

[0024] Figure 4 This is the dose-effect curve of ciprofibrate in inhibiting the growth of HepG2-NTCP cells.

[0025] Figure 5 The contents of HBsAg and HBeAg are shown in the figure when HepG2-NTCP cells are infected with HBV virus and ciprofibrate is added. A is HBeAg and B is HBsAg.

[0026] Figure 6 The content of HBsAg and HBeAg in HepG2-NTCP cells infected with HBV virus for 48 hours after adding ciprofibrate. Among them, A is HBeAg; B is HBsAg. DETAILED DESCRIPTION

[0027] To better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific examples. Other materials, reagents, etc. used in the examples, unless otherwise specified, can be obtained from commercial sources.

[0028] Recovery medium (manufacturer: Shenzhen Liwo Company, catalog number: LV-Rec001), purification medium (manufacturer: Shenzhen Liwo Company, catalog number: LV-PHIK00108), plating medium (manufacturer: Shenzhen Liwo Company, catalog number: LV-WEP001), maintenance medium (manufacturer: Shenzhen Liwo Company, catalog number: LV-WEM00), differentiation medium (manufacturer: TAKARA, catalog number: Y30051).

[0029] Example 1 Binding of small molecule compound probe to hepatitis B surface antigen L-HBsAg protein

[0030] 1. Experimental Methods

[0031] The small molecule compound probes are: sofalcone, prednisone, dexamethasone, isotretinoin, rhein, yamarin lactone B, amlodipine, finasteride, 4-hydroxycinnamic acid, ciprofibrate, testosterone, flumequine and cryptochlorogenic acid.

[0032] 1. Mix each small molecule compound probe with hepatitis B surface antigen L-HBsAg protein in phosphate buffered saline PBS (1 μg / mL) to prepare 20 μl of sample reagent containing 40 μmol small molecule compound probe and 1 μg hepatitis B surface antigen L-HBsAg protein, and incubate with gentle shaking at 21°C for 1 hour to obtain the incubated sample.

[0033] 2. Mix NaVc (sodium acetate, solvent is double distilled water ddH2O), THPTA (tris (3-hydroxypropyl triazole methyl) amine, solvent is dimethyl sulfoxide DMSO), CuSO4 (copper sulfate, solvent is double distilled water ddH2O) and TAMRA-azide (tetramethylrhodamine azide, solvent is DMSO) to prepare a click chemistry reaction mixture containing 1mmol / L NaVc, 100mmol / L THPTA, 1mmol / L CuSO4 and 50mmol / L TAMRA-azide. Add 33μl of the click chemistry reaction mixture to each incubated sample in step 1, incubate at room temperature 25℃ for 1-2h to obtain a sample after click chemistry reaction.

[0034] 3. Use pre-cooled acetone (-20°C) to precipitate the sample after the click chemistry reaction in step 2 overnight (16h) and collect the precipitate.

[0035] 4. Centrifuge the precipitate from step 3 at 12000 rpm and 4°C for 10 min, remove the supernatant, collect the precipitate, and allow the acetone to evaporate.

[0036] 5. Dissolve the precipitate after step 4 in 40 μL 1× loading buffer, load onto SDS-PAGE (sodium dodecyl sulfate-polyacrylamide) gel and separate by electrophoresis, visualized by fluorescence scanning in a laser scanner (manufacturer: AzureBiosystems, model: Sapphire RGBNIR). SDS-PAGE gel was stained with Coomassie brilliant blue for 10 min, washed overnight, and photographed the next day.

[0037] 2. Experimental Results

[0038] like Figure 1 As shown, ciprofibrate specifically binds to L-HBsAg protein, while other small molecule compound probes cannot specifically bind to L-HBsAg protein.

[0039] Example 2 Effect of Ciprofibrate on Human Primary Cells Infected with Hepatitis B Virus HBV

[0040] 1. Experimental Methods

[0041] 1. Prepare two tubes of recovery medium and pre-warm them to 37°C to obtain pre-warmed recovery medium; take out two tubes of frozen human primary hepatocytes from liquid nitrogen, and thaw them in a 37°C water bath by rapid clockwise rotation until a small ice ball is dissolved to obtain thawed human primary hepatocytes; use a 1000μl pipette to gently mix the thawed human primary hepatocytes and then aspirate them, and add them dropwise to the pre-warmed recovery medium to obtain a recovery medium containing human primary hepatocytes.

[0042] 2. Gently rotate and mix the recovery medium containing human primary hepatocytes in step 2, place it in an incubator and let it stand for 30 minutes, then centrifuge it at room temperature (25°C) at 50g for 5 minutes to collect the cells.

[0043] 3. Take 2 ml of purification medium to resuspend the cells treated in step 2, slowly add 1 ml of plating medium along the wall of the tube (obvious stratification), centrifuge at 800g, 4°C for 20 min (the centrifuge speed is set as: acceleration 9, deceleration 1), take the turbid band (living cell layer) between the purification medium and plating medium, and transfer it to a new 15 ml centrifuge tube.

[0044] 4. Add 2 times the volume of plating medium relative to the living cell layer to the cells treated in step 3, mix well, centrifuge at 50g for 5 minutes at room temperature, remove the supernatant, and collect the cells.

[0045] 5. Rinse the 24-well plate coated with rat tail collagen with sterile PBS, resuspend the cells collected in step 4 with 5 ml of plating medium, and plate 2000 cells / well. After 24 hours of plating, replace the medium with maintenance medium (PHH) and culture for 24 hours.

[0046] 6. HBV infection:

[0047] Using differentiation medium (IPS) as solvent, dilute 40% peg8000 (polyethylene glycol with an average molecular weight of 8000) to 4% peg8000 to prepare IPS containing 4% peg8000. Calculate the required volume of HBV virus (20 μl / well) according to the number of wells to be infected, add HBV virus to IPS containing 4% peg8000, mix gently, and prepare an infection system.

[0048] Using the infection system as solvent, prepare 0.25 mM and 0.5 mM ciprofibrate (drug-added group) and 0.2 μM Myrcludex B (bulvir peptide, positive control group) at concentrations respectively, and use the infection system without drug addition as negative control. 500 μl / well is added to the cells cultured in step 5.

[0049] 7. 24 hours after infection in step 6, replace ciprofibrate, Myrcludex and the infection system with maintenance medium and culture for 24 hours. Thereafter, replace the maintenance medium with new one every 48 hours and collect the culture medium; use the Architect system and chemiluminescent microparticle immunoassay (CMIA) kit (manufacturer: Abbott Laboratories) to detect the content of hepatitis B surface antigen HBsAg and hepatitis B e antigen HBeAg in the culture medium.

[0050] 8. On the 10th day after infection in step 7, collect cells and perform immunofluorescence staining:

[0051] (1) Wash the cells once with sterile PBS, fix them with 4% paraformaldehyde for 15 min, and wash the cells three times with 500 μl PBS.

[0052] (2) Mix the cells treated in step (1) with 0.5% Triton X-100 (polyethylene glycol octylphenyl ether, solvent is PBS), permeabilize the membrane at room temperature (25° C.) for 15 min, and then wash the cells three times with 500 μl PBS.

[0053] (3) Block the cells treated in step (2) with ready-made normal goat serum at room temperature (25°C) for 60 minutes, and wash the cells three times with 500 μl / well PBS, 5 minutes each time.

[0054] (4) Gently add the primary antibody against hepatitis B core antigen HBcAg into the wells treated in step (3), incubate at 4°C overnight (12 h), and wash the cells three times with 500 μl / well PBS, 5 min each time.

[0055] (5) Incubate the cells treated in step (4) with mouse secondary antibody on a shaker at room temperature in the dark for 1 hour; after the incubation, wash the cells three times with 500 μl / well PBS, 5 min each time, in the dark.

[0056] (6) Add DAPI (4',6-diamidino-2-phenylindole) to cover the cell surface after treatment in step (5), perform nuclear counterstaining, and take pictures using an inverted microscope IX73.

[0057] 2. Experimental Results

[0058] (1) Figure 2 A and Figure 2 As shown in B, by detecting the antigen expression levels in the ciprofibrate-added group and the control group, it can be seen that the antigen expression level in the ciprofibrate-added group was significantly reduced compared with the control group.

[0059] (2) Figure 3As shown, by comparing the immunofluorescence of the ciprofibrate-added group with that of the control group, it can be seen that the HBcAg fluorescence in the ciprofibrate-added group was reduced.

[0060] Ciprofibrate inhibits HBV infection of human primary cells during the HBV infection stage, thereby reducing the expression of HBsAg and HBeAg.

[0061] Example 3 IC of ciprofibrate inhibiting the growth of HepG2-NTCP cells (a liver cancer cell line overexpressing sodium taurocholate cotransporting polypeptide (NTCP)-1) 50

[0062] 1. Experimental Methods

[0063] 1. HepG2-NTCP cells were plated into 96-well plates, with 8,000 cells per well, and cultured in Dulbecco's Modified Eagle Medium (DMEM) containing 10% fetal bovine serum in a cell incubator at 37°C and 5% CO2 for 24 h.

[0064] 2. Add ciprofibrate at final concentrations of 5 mM, 1 mM, 200 μM, 40 μM, 8 μM, 1.6 μM, 320 nM, 64 nM and 12.8 nM to the wells in step 1, and replace one column with DEME medium containing a new volume concentration of 10% fetal bovine serum as the experimental control well.

[0065] 3. Place the cells treated in step 2 in an incubator and culture them. After 24 hours, add 10 μl of CCK8 reagent (Cell Counting Kit-8 cell counting reagent) to each well, incubate in an incubator at 37°C and 5% CO2 for 1 hour, and detect the absorbance using an enzyme reader.

[0066] 2. Experimental Results

[0067] like Figure 4 As shown, the IC of ciprofibrate for inhibiting the growth of HepG2-NTCP cells 50 This example studies the reasonable concentration of ciprofibrate, and the concentration of ciprofibrate at 500 μM and 250 μM will not affect cell proliferation.

[0068] Example 4 Effect of Ciprofibrate on HepG2-NTCP Cells Before and After HBV Infection

[0069] 1. Experimental Methods

[0070] 1. Plate HepG2-NTCP cells in a 24-well plate moistened with rat tail collagen, with a cell density of 0.4 M in each well. Shake to evenly plate the cells, and culture them in a cell incubator at 37°C and 5% CO2 using DEME medium containing 10% fetal bovine serum by volume. After the cells adhere, replace the medium with differentiation medium (IPS) and culture for 24 hours.

[0071] 2. The HepG2-NTCP cells cultured in step 1 were infected with HBV virus in the same manner as in Example 2, wherein the drug addition group was divided into two groups:

[0072] (1) Group A: HBV virus infection and addition of ciprofibrate: using the infection system as the solvent, 0.25 mM and 0.5 mM ciprofibrate were prepared as the drug-adding group, 500 μl / well, and added to the HepG2-NTCP cells cultured in step 2. After 24 hours of infection, the solvent of 0.25 mM and 0.5 mM ciprofibrate and 0.2 μM Myrcludex was replaced with IPS medium, and the cells were cultured for 24 hours. The solvent of 0.25 mM and 0.5 mM ciprofibrate and 0.2 μM Myrcludex was replaced with PHH medium, and the cells were cultured. The drugs were added in the form of liquid replacement every 48 hours, and the culture medium was collected.

[0073] (2) Group B: HBV virus infection followed by the addition of ciprofibrate: 500 μl / well of the infection system was added to the HepG2-NTCP cells cultured in step 2. After 24 hours of infection, the infection system was replaced with IPS medium and cultured for 24 hours. Ciprofibrate with PHH as solvent was added at concentrations of 0.25 mM and 0.5 mM, respectively, as the drug-addition group, at 500 μl / well. The drug was added by changing the medium every 48 hours, and the culture medium was collected.

[0074] 3. Use the Architect system and chemiluminescent microparticle immunoassay (CMIA) kit (Abbott Laboratories) to detect the content of hepatitis B surface antigen HBsAg and hepatitis B e antigen HBeAg in the culture medium of step 2.

[0075] 2. Experimental Results

[0076] like Figure 5 A and Figure 5 As shown in B, in group A, the drugs were added simultaneously with HBV infection, and the levels of HBsAg and HBeAg in the supernatant of the ciprofibrate 0.25mM group and 0.5mM group were lower than those of the control group.

[0077] like Figure 6 A and Figure 6As shown in B, when group B was given the drug 48 hours after HBV infection, the HBeAg content in the supernatant of the 0.25mM and 0.5mM ciprofibrate groups decreased, and the HBsAg content in the supernatant of the 0.5mM ciprofibrate group decreased compared with the control group, while the HBsAg content in the 0.25mM ciprofibrate group did not decrease significantly compared with the control group.

[0078] In summary, ciprofibrate inhibits viral biosynthesis, inhibits viral release, and enhances the host's antiviral ability.

[0079] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.

Claims

1. The application of ciprofibrate in the preparation of drugs against hepatitis B virus.

2. The use according to claim 1, characterized in that: The medicine is a medicine for inhibiting hepatitis B virus infection.

3. The use according to claim 1, characterized in that: The drug is a drug for inhibiting the replication and / or proliferation of hepatitis B virus.

4. The use according to claim 1, characterized in that: The drug is a drug for reducing the expression amount of at least one of hepatitis B surface antigen HBsAg, hepatitis B e antigen HBeAg and hepatitis B core antigen HBcAg.

5. The use according to any one of claims 1 to 4, characterized in that: The medicine further contains pharmaceutically acceptable additives and / or excipients and / or carriers.

6. The use according to claim 5, characterized in that: The medicine is in the form of tablets, granules or liquid preparations.

7. Use of ciprofibrate in the preparation of a drug for preventing and / or treating diseases caused by hepatitis B virus.

8. The use according to claim 7, characterized in that: The medicine is a medicine for preventing and / or treating hepatitis B.

9. The use according to claim 7, characterized in that: The medicine is a medicine for preventing and / or treating liver failure, liver cirrhosis and hepatocellular carcinoma and complications thereof caused by hepatitis B virus.

10. The use according to claim 7, characterized in that: The medicine is an anti-hepatitis B virus medicine.

Citation Information

Patent Citations

  • Compostions and methods for treating chronic inflammation and inflammatory diseases

    CN103391768A

  • Composition and therapies for hyperlipidaemia-associated disorders

    US20040009961A1